Skip to content

Glaukos Corp Price, Chart & Factor Exposure

Free Data & Analytics Access

Latest earnings: October 28, 2026 results vs estimates

Glaukos Corp · E.GKOS.NYSE · United States
Use symbol E.GKOS.NYSE in our API & Excel add-in to retrieve this data ↓
242.48
(+0.34%)
? Live Prices updated every 5-seconds. Momentum Factor ranges from -100 to +100 and is the mean of four timeframe signals (1 Day, 1 Week, 1 Month, 3 Months), where each timeframe is +1 if return is above 0 and -1 otherwise. Trend Factor ranges from -100 to +100 and is the mean of eight signals across 1-month, 3-months, 6-months, and 1-year, using price vs moving average and moving average slope (+1 or -1). A rollover occurs when trend flips sign. Bubble Risk is the z-score of current price vs 1-year price: (Current Price - 250 trading days SMA) / (250 days price standard deviation). Values above +2.5 indicate overbought; below -2.5 oversold. Realized Volatility (20-days) is the standard deviation of daily returns over the past 20 trading days multiplied by sqrt(252).
Momentum 100%
Trend 100%
Bubble Risk LOW
Realised Volatility (20D) 123.91%

Glaukos Corp Forecast

Glaukos Corp short-term momentum is strongly positive (up over 4 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term BUY signal. The long-term trend is strongly positive (8 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term BUY signal. Based on 20-day realised volatility of 123.9% a year, a typical one-standard-deviation range is 200.16–284.80 over a week, 155.75–329.21 over a month and -57.97–542.93 over a year. (Signals as of 1 Nov 2026.)

Glaukos Corp Price Chart

MacroFinance.ai
Market/MacroIndicatorNowChangeRange
Quantitative
Glaukos Corp
Momentum (composite)
—
ⓘLatest reading of Momentum (composite).
Glaukos Corp
Relative Volume (21d)
—
ⓘLatest reading of Relative Volume (21d).
Glaukos Corp
Signal
0
ⓘLatest reading of Signal.
Fundamental
Valuation
Glaukos Corp
P/S
21.50x
Stretched vs own history
QoQ +22.0%
YoY +76.6%
now 21.495210.88 low21.78 high
ⓘP/S As of 22 Nov 2026.See Glaukos Corp returns when P/S looked like now →Opens Return analysis with the filter P/S within ±5% of today
Glaukos Corp
P/B
20.69x
Stretched vs own history
QoQ +30.7%
YoY +178.4%
now 20.68787.93 low20.96 high
ⓘP/B As of 22 Nov 2026.See Glaukos Corp returns when P/B looked like now →Opens Return analysis with the filter P/B within ±5% of today
Glaukos Corp
EV/Sales
21.16x
Stretched vs own history
QoQ +22.1%
YoY +79.1%
now 21.155210.56 low21.44 high
ⓘEV/Sales As of 22 Nov 2026.See Glaukos Corp returns when EV/Sales looked like now →Opens Return analysis with the filter EV/Sales within ±5% of today
Glaukos Corp
FCF Yield
0.2%
Strong vs own history
QoQ −314.9%
YoY −150.3%
now 0.2427-0.45 low0.26 high
ⓘFCF Yield As of 22 Nov 2026.See Glaukos Corp returns when FCF Yield looked like now →Opens Return analysis with the filter FCF Yield within ±5% of today
Glaukos Corp
Earnings Yield
-1.1%
Strong vs own history
QoQ −34.3%
YoY −25.3%
now -1.1443-3.36 low-1.13 high
ⓘEarnings Yield As of 22 Nov 2026.See Glaukos Corp returns when Earnings Yield looked like now →Opens Return analysis with the filter Earnings Yield within ±5% of today
Glaukos Corp
Market Cap
$14.8B
Highest in 5 years
QoQ +37.4%
YoY +159.5%
now 14838.80615,579 low15,037 high
ⓘMarket Cap As of 22 Nov 2026.See Glaukos Corp returns when Market Cap looked like now →Opens Return analysis with the filter Market Cap within ±5% of today
Balance-Sheet Health
Glaukos Corp
Net Debt
-$235M
Low vs own history
QoQ +28.0%
YoY +38.6%
now -234.716-234.72 low-139.12 high
ⓘNet Debt As of 22 Nov 2026.See Glaukos Corp returns when Net Debt looked like now →Opens Return analysis with the filter Net Debt within ±5% of today
Glaukos Corp
Current Ratio
4.57x
Weak vs own history
QoQ −9.3%
YoY −12.0%
now 4.5744.57 low5.43 high
ⓘCurrent Ratio As of 22 Nov 2026.See Glaukos Corp returns when Current Ratio looked like now →Opens Return analysis with the filter Current Ratio within ±5% of today
Glaukos Corp
Quick Ratio
4.09x
Weak vs own history
QoQ −8.3%
YoY −8.4%
now 4.09244.06 low4.73 high
ⓘQuick Ratio As of 22 Nov 2026.See Glaukos Corp returns when Quick Ratio looked like now →Opens Return analysis with the filter Quick Ratio within ±5% of today
Glaukos Corp
Interest Coverage
-35.13x
Weak vs own history
QoQ −8.1%
YoY +117.2%
now -35.1262-41.31 low-16.17 high
ⓘInterest Coverage As of 22 Nov 2026.See Glaukos Corp returns when Interest Coverage looked like now →Opens Return analysis with the filter Interest Coverage within ±5% of today
Glaukos Corp
Debt / Equity
0.14x
Mid-range vs own history
QoQ −5.6%
YoY +4.9%
now 0.14220.14 low0.21 high
ⓘDebt / Equity As of 22 Nov 2026.See Glaukos Corp returns when Debt / Equity looked like now →Opens Return analysis with the filter Debt / Equity within ±5% of today
Glaukos Corp
Piotroski F-Score
5
Mid-range vs own history
QoQ +66.7%
YoY 0.0%
now 53 low5 high
ⓘPiotroski F-Score As of 22 Nov 2026.See Glaukos Corp returns when Piotroski F-Score looked like now →Opens Return analysis with the filter Piotroski F-Score within ±5% of today
Glaukos Corp
Altman Z-Score
33.25
Strong vs own history
QoQ +26.5%
YoY +130.2%
now 33.253213.02 low33.71 high
ⓘAltman Z-Score As of 22 Nov 2026.See Glaukos Corp returns when Altman Z-Score looked like now →Opens Return analysis with the filter Altman Z-Score within ±5% of today
  18 members-only factors: Revenue Growth, Revenue CAGR 3Y, Earnings Growth, EBITDA Growth and moreSign up
Accounting Red Flags
  19 members-only factors: Sloan Accruals, Cash-Earnings Gap, Days Sales in Receivables Index, Gross Margin Index and moreSign up
Global Risk
  22 members-only factors: MacroFinance Risk Index, VIX, VSTOXX, VIX Term Structure and moreSign up
Teal = supportive for Glaukos Corp, red = a headwind, grey = neutral. Hover or tap ⓘ for how each factor works and to see returns in similar conditions.

Glaukos Corp fundamentals: income statement, balance sheet & cash flow

Glaukos Corp reported revenue of $507.4m and net income of -$187.7m in FY2025, the year ended 31 December 2025 — revenue up 32.3% and net income down 28.2% on the prior year. Free cash flow was -$54.0m. These figures are as reported in the filings, not restated: 14 fiscal years and 55 quarters of history, back to December 2012. 173 FINRA short-interest settlements are published alongside them, back to June 2019.

Revenue (FY2025)
$507.4m
+32.3%
Net income
-$187.7m
-28.2%
Gross margin
77.49%
Free cash flow
-$54.0m
+20.1%
Net debt
$48.8m
Shares short (30 Oct 2026)
4.48m
2.85 days to cover
Glaukos Corp income statement, annual, as reported · USD millions unless stated
USD millionsFY2025FY2024FY2023FY2022FY2021
Period end31 Dec 202531 Dec 202431 Dec 202331 Dec 202231 Dec 2021
Revenue507.4383.5314.7282.9294.0
Cost of revenue114.294.075.669.066.6
Gross profit393.2289.5239.1213.9227.4
Research & development150.6136.4138.8123.3101.0
Selling, general & admin.331.7————
Operating income-86.7-122.4-128.7-82.3-32.9
EBITDA-146.1-95.6-82.1-48.8-1.5
Interest expense4.610.013.613.713.4
Pre-tax income-193.0-145.6-133.7-98.4-49.3
Income tax-5.40.80.90.80.3
Net income-187.7-146.4-134.7-99.2-49.6

Download Glaukos Corp fundamentals

Get the fundamentals as
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_fundamentals&symbol=E.GKOS.NYSE&statement=all&freq=a&format=csv&years=10
DownloadLast 10 fiscal years, no login.
The free download stops at 10 fiscal years. A free account unlocks all 14 fiscal years and 55 quarters, the filing vintages behind each number and API access.
Create free account

Figures in USD, statements as filed and FINRA consolidated short interest. A cell is left blank where the filing does not report it or where the reported figure fails the statement’s own arithmetic. Short interest is the consolidated FINRA figure for the settlement date shown, published seven to eight business days later.

Research on Glaukos Corp

Explore MacroFinance macro & markets research and analysis.

Browse all financial research →

Glaukos Corp Trading Strategies

58 backtested tactical asset allocation strategies hold SPY (US market) or XLV (Health Care sector), the closest tradable exposure to Glaukos Corp; 28 of them are invested now. Strategies currently invested are listed first.

Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.

From creators

See all 58 strategies holding SPY, XLV →

Statistical Distribution of Returns

Plus

How Glaukos Corp’s returns are distributed — and how they change in a given market regime.

Regime filters

Market/Macro Indicator Criteria Value And (for Between) Action

No regime filter yet — the chart below shows every period. Add a factor condition, or pick a popular regime.

MacroFinance.ai
Full return statistics
Statistic All periods Matching
  Sharpe, maximum drawdown and the full percentile table are part of Plus. Unlock with Plus
Know how Glaukos Corp behaves before the regime turns Plus unlocks the full return history, unlimited factor conditions, regime-versus-baseline statistics and export — on every market, stock, ETF and index.

About Glaukos Corp (United States)

Glaukos Corp is a listed security in the United States. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).

Last updated: November 22, 2026

Frequently asked questions

What is Glaukos Corp?
Glaukos Corp is a listed security in the United States. On MacroFinance its page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data.
What is the latest Glaukos Corp price?
The latest close is 242.48 (1 Nov 2026), +0.34% on the day. The price at the top of the page refreshes during the trading day.
Is Glaukos Corp in an uptrend?
As of 1 Nov 2026, short-term momentum is strongly positive (4 of 4 look-backs up: 5, 10, 20 and 30 trading days) and the long-term trend is strongly positive (8 of 8 checks up on its 50- to 200-day moving averages). Bullish when both are positive, bearish when both are negative.
How volatile is Glaukos Corp?
20-day realised volatility is 123.9% a year (1 Nov 2026), which implies a typical one-standard-deviation move of about 35.8% over a month and 17.5% over a week.
What factors affect Glaukos Corp?
The Factors section lists the signals, relative-value, risk-model and macro factors linked to Glaukos Corp, grouped as Quantitative Factors, Fundamental Factors, Accounting Red Flags, Global Risk Factors, each with its latest reading. Some factors are open to everyone; the rest need a MacroFinance plan.
Which trading strategies trade Glaukos Corp?
58 backtested tactical asset allocation strategies trade Glaukos Corp through SPY, XLV; 28 of them hold it now. The Trading Strategies section lists them with their current weight, CAGR, Sharpe ratio and maximum drawdown.
How are Glaukos Corp returns analysed?
The Statistical Distribution of Returns section shows the distribution of Glaukos Corp daily, weekly, monthly, 2-month and 3-month returns with count, annualised average return, volatility, Sharpe ratio and maximum drawdown, and lets you filter the history by factor conditions, e.g. only periods when momentum was positive. A free account tests up to 2 factor conditions over the last 1 year of history; a Plus plan unlocks the full history, unlimited conditions, the regime statistics and the export.
Where can I download free Glaukos Corp historical data?
In the Free historical data section of this page: the last 10 years of Glaukos Corp daily closes as CSV or JSON, no login needed. A free account unlocks the full history, Excel and API access.

Free Glaukos Corp historical data (last 10 years)

Browse or instantly download the last 10 years of Glaukos Corp daily price history. A free account unlocks the full history, an Excel export with factors, and API access.

Get the data as
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.GKOS.NYSE&format=csv&years=10
DownloadLast 10 years, no login.
DateClose
2026-11-20237.31
2026-11-19238.1
2026-11-18233.08
2026-11-17243.25
2026-11-16244.88
2026-11-13245.72
2026-11-12246.03
2026-11-11247.16
2026-11-10236.19
2026-11-09238.74
Loading last 10 years…
The table and downloads stop at 10 years. A free account unlocks the full history, the Excel add-in and API access.
Create free account

About this stock

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. The company also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. In addition, the company develops iLink, a device used for the treatment of keratoconus without the removal of the epithelium; ILution, a platform of cream-based drug formulation applied to the outer surface of the eyelid for drop less transdermal delivery of pharmaceutically active compounds for the treatment of anterior segment eye disorders; and retinal XR platform to treat age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and other posterior segment retinal diseases. It sells its products to ambulatory surgery centers, hospitals, and physician private practices through a direct sales organization, direct sales subsidiaries, and distributors. The company was formerly known as Transdx, Inc. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.